Clonal Monocytosis Links Identified in Recent Study
Researchers uncovered distinct clinical and genetic markers that help predict how certain blood precursor states progress.
Updated on Sept. 28, 2026 in Cancer
A new study of 958 patients with sustained monocytosis has identified specific clinical and molecular differences in precursor states. These findings offer clearer insight into the risk of progression to myeloid neoplasms for those living with these conditions.
Why it matters
Understanding these distinct precursor states helps clinicians better classify patient risk levels, which is crucial for managing the transition from benign blood findings to potentially serious myeloid neoplasms.
This study evaluated 958 patients with sustained monocytosis over a median follow-up of 31 months. It identified distinct genetic mutation profiles, such as TET2 and ASXL1, which vary in frequency between precursor states and oligo monocytic chronic myelomonocytic leukemia.
The details
Researchers evaluated patients with monocytosis of at least 0.5 times 10 to the 9th per liter by integrating morphological assessments with genomic sequencing. The analysis revealed that TET2 mutations were present in 60 percent of OM-CMML patients, while DNMT3A mutations were more prevalent in precursor groups. By comparing these molecular patterns, the team successfully differentiated between stable precursor states and those with higher risks of clinical progression.
Timeline
The median duration of follow-up for the study cohort was 31 months.
Health Landscape
This study refines the classification of blood precursor states within the existing framework of the WHO classification of myeloid neoplasms. It shifts the diagnostic focus from simple cell counts toward a more precise, molecularly driven understanding of disease progression.
If you have been diagnosed with sustained monocytosis, these findings emphasize the importance of regular monitoring to track potential changes in your blood markers. Discuss your specific genetic testing results and progression risk factors with your hematologist to determine your personal care plan.
The takeaway
Distinguishing between precursor states is essential for identifying patients at higher risk of developing myeloid neoplasms. Speak with your physician about the clinical relevance of any observed monocytosis and whether genetic screening is appropriate for your specific situation.
Further reading
For more information on how doctors classify blood disorders and related risks, visit our Cancer section.
